Fulvestrant
Her2-Receptor Negative Breast Cancer
Explore 186 assets in Her2-Receptor Negative Breast Cancer →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Olema Pharmaceuticals, Inc.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07085767CT.gov Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06982521CT.gov Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06756932CT.gov BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05554354CT.gov Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) | — | Terminated | — | — | — |
NCT06179303CT.gov Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06253195CT.gov BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | — | Completed | — | — | — |
NCT06120283CT.gov BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06016738CT.gov OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT04901299CT.gov Fulvestrant + Neratinib In Breast Cancer | — | Withdrawn | — | — | — |
NCT05826964CT.gov Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer | — | Active Not Recruiting | — | — | — |
Show 34 more trialsShow fewer
NCT05564377CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | — | Recruiting | — | — | — |
NCT05759949CT.gov First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | — | Completed | — | — | — |
NCT05735080CT.gov Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | — | Recruiting | — | — | — |
NCT05101564CT.gov Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer | — | Completed | — | — | — |
NCT05594095CT.gov SNF Platform Study of HR+/ HER2-advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05452213CT.gov Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients | — | Recruiting | — | — | — |
NCT05467891CT.gov Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05524584CT.gov Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05508906CT.gov Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06525675CT.gov Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) | — | Completed | — | — | — |
NCT05362760CT.gov Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management | — | Recruiting | — | — | — |
NCT05252416CT.gov (VELA) Study of BLU-222 in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04985266CT.gov A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05216432CT.gov First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT04738292CT.gov Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) | — | Terminated | — | — | — |
NCT05054374CT.gov A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer | — | Completed | — | — | — |
NCT04965688CT.gov Biology Guided Therapy for Breast Cancer for ER Positive | — | Terminated | — | — | — |
NCT04498520CT.gov Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | — | Withdrawn | — | — | — |
NCT04762979CT.gov Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03939897CT.gov Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03554044CT.gov T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | — | Completed | — | — | — |
NCT03854903CT.gov WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor | — | Completed | — | — | — |
NCT03691493CT.gov Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis | — | Completed | — | — | — |
NCT03633331CT.gov Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03377101CT.gov Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer | — | Withdrawn | — | — | — |
NCT03477396CT.gov Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03462251CT.gov Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line | — | Completed | — | — | — |
NCT03294694CT.gov Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | — | Terminated | — | — | — |
NCT02860000CT.gov Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | — | Completed | — | — | — |
NCT02760030CT.gov Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT02894398CT.gov Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | — | Completed | — | — | — |
NCT02404051CT.gov Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT02269670CT.gov Phase II Study of Everolimus Beyond Progression | — | Terminated | — | — | — |
NCT00390455CT.gov Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Her2-Receptor Negative Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fulvestrant (this asset) | Olema Pharmaceuticals, Inc. | Approved | BB · 66 |
| Palbociclib | Helwan University | P2 | BBB |
| Exemestane | National Cancer Institute (NCI) | P4 | BBB |
| Pembrolizumab | UNC Lineberger Comprehensive Cancer Center | P2 | BBB |
| Atezolizumab | TransThera Sciences (Nanjing), Inc. | P2 | BB |
| Docetaxel | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P2/3 | BB |
| Palazestrant | Olema Pharmaceuticals, Inc. | P3 | BB |
| Capecitabine | Kristina A. Fanucci | P4 | BB |
| Durvalumab | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Her2-Receptor Negative Breast Cancer cohort
Other indications for Fulvestrant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BB · 70 |
| Breast Cancer | — | P4 | BB · 69 |
| Invasive Breast Carcinoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fulvestrant in Her2-Receptor Negative Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fulvestrant-her2-receptor-negative-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →